seduce
发表于 2025-3-30 08:43:44
Management Innovation and Big Dataastatic ovarian carcinoma from primary breast carcinoma is discussed in more detail, as well as differentiating metastatic neuroendocrine tumors from primary breast carcinomas with neuroendocrine differentiation.
抗体
发表于 2025-3-30 13:11:31
Management Innovation and Big Dataarance depending on the result of the provisional node assessment. Methods for dealing with these different biopsy types are discussed. The chapter ends with a discussion of carcinoma of unknown primary (CUP) origin occasionally seen in axillary lymph nodes.
Compatriot
发表于 2025-3-30 19:27:14
Dealing with the Gross Specimen,adjuvant chemotherapy, and axillary lymph node specimens are dealt with in other Chaps. (4, 5, 2, and 14, respectively). The accounts in this chapter are mainly based on the practice at Charing Cross Hospital, London.
Panacea
发表于 2025-3-30 22:01:25
Problematic Core Biopsies,using diagnostic difficulties, such as the B3 lesions, of uncertain malignant potential, as well as potentially problematic malignant lesions, albeit these make up a minority of a pathologist’s routine practice.
Tailor
发表于 2025-3-31 01:17:54
http://reply.papertrans.cn/20/1907/190615/190615_55.png
恶意
发表于 2025-3-31 06:41:25
http://reply.papertrans.cn/20/1907/190615/190615_56.png
全能
发表于 2025-3-31 10:44:20
Axillary Lymph Node Biopsies,arance depending on the result of the provisional node assessment. Methods for dealing with these different biopsy types are discussed. The chapter ends with a discussion of carcinoma of unknown primary (CUP) origin occasionally seen in axillary lymph nodes.
endure
发表于 2025-3-31 13:51:51
http://reply.papertrans.cn/20/1907/190615/190615_58.png
MOT
发表于 2025-3-31 18:03:20
Molecular Classification and Testing of Breast Carcinoma,he specific molecular aberrations driving tumor growth. This chapter describes models for the molecular classification of breast cancer, current genetic signatures available for predicting prognosis, and future prospects for monitoring disease and response to therapy.
夹死提手势
发表于 2025-4-1 00:06:19
Dealing with the Gross Specimen,g with other specimens is also briefly discussed as dealing with core biopsies, specimens from patients with DCIS, specimens from patients who had neoadjuvant chemotherapy, and axillary lymph node specimens are dealt with in other Chaps. (4, 5, 2, and 14, respectively). The accounts in this chapter